mCRC
FDA Grants Accelerated Approval to Braftovi for Some Patients With Metastatic Colorectal Cancer
The FDA granted accelerated approval to encorafenib (Braftovi, Array BioPharma, a subsidiary of Pfizer) with ...
DECEMBER 23, 2024
New First-Line Option for Highly Mutated CRC?
A new study shows that the dual immunotherapy combination of nivolumab (Opdivo, Bristol Myers Squibb [BMS]) plus ...
FEBRUARY 12, 2024
Should Disappearing Colorectal Liver Metastases Be Resected?
How should disappearing colorectal liver metastases be managed?
SEPTEMBER 24, 2021
KEYNOTE-177 Delivers Final Results
In patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, front-line ...
AUGUST 11, 2021
PANAMA Supports Panitumumab Maintenance in RAS Wild-Type mCRC
Panitumumab plus 5-fluorouracil and leucovorin (5-FU/LV) is superior to 5FU/LV alone as maintenance therapy ...
JULY 26, 2021
Cetuximab Every 2 Weeks as Effective as Weekly
On April 6, the FDA approved a regimen of 500 mg/m2 of cetuximab (Erbitux, Lilly) every two weeks for K-Ras ...
APRIL 26, 2021
New Dosing Regimen Approved for Erbitux
The FDA approved a regimen of 500 mg/m2 of cetuximab (Erbitux, ImClone) given intravenously over 120 minutes every ...
APRIL 8, 2021
FDA Grants New Indication for Opdivo + Yervoy Combo in mCRC
The FDA granted a new indication for Opdivo and Yervoy to treat adults and children 12 years of age and older with ...
JULY 12, 2018
Opdivo Approved for Previously Treated MSI-H or dMMR mCRC
Nivolumab was granted accelerated approval for the treatment of patients with microsatellite instability–high ...
AUGUST 3, 2017
Vectibix Approved for Wild-Type RAS Metastatic CRC
The FDA has approved panitumumab and companion diagnostic for patients with wild-type mCRC.
JULY 5, 2017
AACR Report: HER2-Targeted Rx Effective in HER2+ mCRC
In heavily pretreated patients with HER2-positive mCRC, a combination of trastuzumab and lapatinib provided ...
APRIL 6, 2017